Clinical Trial

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase 3 double-blind clinical trial arm to test Ropeginterferon alfa-2b (P1101) in adult patients with Primary Myelofibrosis (PMF) at early stage or low to medium risk. Participants will receive the study drug/placebo bi-weekly and have an assessment visit every 4 weeks. The ratio of study drug to placebo group is 2:1.
Protocol Amendment History 1 change
minor Trial sites expanded: 2 -> 73 locations 2026-08-14
Trial Details
NCT Number NCT06468033
Lead Sponsor PharmaEssentia
Conditions Primary Myelofibrosis, Myeloproliferative Neoplasm
Enrollment 160 participants
Start Date 2025-07-18
Primary Completion 2027-11-18 (estimated)
Study Completion 2029-01-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-13